Dovitinib lactate is under clinical development by Allarity Therapeutics and currently in the Phase II and Pre-Registration in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Dovitinib lactate’s likelihood of approval (LoA) and phase transition for Breast Cancer took place on 21 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Dovitinib lactate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Dovitinib lactate overview

Dovitinib lactate (TKI258, CHIR-258) is under development for the treatment of breast cancer, hepatocellular carcinoma, endometrial cancer, gastrointestinal stromal tumor (GIST), osteosarcoma and metastatic renal cell carcinoma. It inhibits PDGFR beta, CSF 1R, KIT, FLT3, VEGFR, TrkA, RET and FGFRs. Inhibition of tyrosine kinase results in the induction of endothelial cell apoptosis, a reduction in tumor vasculature, anti-angiogenesis and the inhibition of tumor cell proliferation and migration.

It was under development by Novartis for the treatment of solid tumors such as colorectal cancer, metastatic HER2 negative breast cancer, advanced scirrhous gastric carcinoma, bladder cancer, metastatic adenoid cystic carcinoma, paragangliomas, pancreatic endocrine tumor, adrenocortical carcinoma, gastric cancer, glioblastoma, non-small cell lung cancer, Von Hippel-Lindau syndrome, transitional cell carcinoma (urothelial cell carcinoma), advanced hepatocellular carcinoma, adenoid cystic carcinoma of the salivary gland, pancreatic cancer, relapsed or refractory multiple myeloma, metastatic melanoma and acute myelocytic leukemia.

Allarity Therapeutics overview

Allarity Therapeutics (Allarity) is a precision medicine company that develops drugs for cancer. The company is investigating Dovitinib, a pan-tyrosine kinase inhibitor targeting RCC (renal cell cancer), gastrointestinal stromal tumor (GIST), liver, metastatic breast, and endometrial cancer; and Stenoparib, a dual PARP and Tankyrase inhibitor against ovarian cancer. It is also evaluating Ixempra (ixabepilone), a cell-cycle specific antimicrotubule agent; and LiPlaCis, a target controlled liposome formulation to treat metastatic breast cancer; and 2X-111 targeting glioblastoma multiform (GBM) and brain metastases of breast cancer (mBC). Allarity utilizes its proprietary drug response predictor (DRP) diagnostic platform technology that models human tumor biology and predicts cancer patient response. The company has operational presence in Hoersholm, Denmark. Allarity is headquartered in Cambridge, Massachusetts, the US.

Quick View Dovitinib lactate LOA Data

Report Segments
  • Innovator
Drug Name
  • Dovitinib lactate
Administration Pathway
  • Oral
Therapeutic Areas
  • Genetic Disorders
  • Oncology
Key Developers
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.